特力利汀治疗2型糖尿病长期效果的Markov模型

doi:10.12092/j.issn.1009-2501.2018.01.013

中国临床药理学与治疗学 ›› 2018, Vol. 23 ›› Issue (1): 65-72.doi: 10.12092/j.issn.1009-2501.2018.01.013

特力利汀治疗2型糖尿病长期效果的Markov模型

张春燕¹，范小冬¹，秦元²，孔文强³，周春阳¹，杜彪^1,4

¹川北医学院药学院，南充 637000，四川；²大理大学药学与化学学院，大理 671000，云南；³西南医科大学药学院，泸州 646000，四川；⁴ 重庆三峡中心医院药学部，重庆 404000

收稿日期:2017-07-14 修回日期:2017-08-22 出版日期:2018-01-26 发布日期:2018-02-07
通讯作者: 杜彪，男，主任药师，硕士生导师，研究方向：循证药学。 Tel：023-58103184 E-mail：dubiao1967@aliyun.com
作者简介:张春燕，女，药师，硕士研究生，研究方向：循证药学。 E-mail：kaixinbaobeizcy@163.com
基金资助:
重庆市社会事业与民生保障科技创新专项(cstc2015shmszx120073)(cstc2017shmsA130105)；重庆市万州区科技计划基金资助项目（201403055）

Markov model to assess long-term effects of teneligliptin in treatment of type 2 diabetes mellitus

ZHANG Chunyan ¹, FAN Xiaodong ¹, QIN Yuan², KONG Wenqiang³, ZHOU Chunyang¹, DU Biao ^1,4

¹School of Pharmacy, North Sichuan Medical College, Nanchong 637000, Sichuan, China; ²College of Pharmacy and Chemistry, Dali University, Dali 671000, Yunnan, China; ³ School of Pharmacy, Southwest Medical University, Luzhou 646000, Sichuan, China; ⁴ Department of Pharmacy, Chongqing Three Gorges Central Hospital, Chongqing 404000, China

Received:2017-07-14 Revised:2017-08-22 Online:2018-01-26 Published:2018-02-07

摘要/Abstract

摘要：

目的: 系统评价二肽基肽酶Ⅳ（DPP-4）抑制剂特力利汀治疗2型糖尿病的疗效，并采用Markov模型评估其长期疗效。方法: 计算机检索PubMed、The Cochrane Library、Embase和中国知网、万方医学网、维普等数据库，并追溯纳入的参考文献和手工检索相关杂志，时限为建库至2017年6月。由2位研究员根据事先制定的纳入排除标准筛选随机对照试验，提取文献基本信息及数据、评价文献质量。采用RevMan5.3软件对疗效指标、安全性指标进行Meta分析，并建立Markov模型评估长期疗效。结果: 共纳入5篇随机对照试验（RCT），包括糖尿病患者903例。Meta分析结果显示：特力利汀明显降低主要指标糖化血红蛋白［SMD=-0.87, 95%CI(-0.99,-0.76), P<0.000 01］、降低次要指标空腹血糖［SMD=-0.71,95%CI(-0.85,-0.58), P<0.000 01］，增加β细胞功能指数［SMD=0.46, 95%CI(0.33,0.60), P<0.000 01］，优于安慰剂对照组，差异有统计学意义(P<0.05)；减少次要指标胰岛素抵抗指数方面，两组差异无统计学意义(P>0.05)。Markov模型结果表明，特力利汀可以降低糖尿病死亡人数。结论: 新型降血糖药物DPP-4抑制剂特力利汀治疗2型糖尿病，降糖疗效显著，不增加低血糖的发生，还可以对胰岛β细胞功能起保护作用，降低糖尿病并发症和死亡的发生。

关键词: 二肽基肽酶Ⅳ抑制剂, 特力利汀, 2型糖尿病, 系统评价, Markov模型

Abstract:

AIM: To investigate the long-term efficacy and safety of teneligliptin as dipeptidyl -peptidase Ⅳ(DPP-4) inhibitor for type 2 diabetes mellitus and estimate the long-term efficacy. METHODS: Search the literature in databases of PubMed, The Cochrane Library, Embase, CNKI, Wan Fang, CQVIP and so on. Randomized controlled trials (RCT) of teneligliptin for the treatment of T2DM were collected with time limit from establishment to June, 2017. References and related professional magazine were also retrieved manually. Two researchers independently screened these literatures according to the inclusion and exclusion criteria, extracted basic information and assessed the methodological quality of included studies. Meta-analysis of the indexes was performed by using RevMan 5.3. Evaluate the long-term efficacy by establishing a new Markov model. RESULTS: Five RCTs were collected, including 903 diabetic patients. The results of meta-analysis showed teneligliptin can effectively reduce the main index HbA1c ［SMD=-0.87, 95%CI(-0.99,-0.76), P<0.000 01］ and FPG［SMD=-0.71, 95%CI (-0.85,-0.58), P<0.000 01］, increase the secondary index HOMA-beta ［SMD=0.46, 95%CI (0.33,0.60), P<0.000 01］ than placebo group. And there was significant difference between them (P<0.05). And Markov model showed teneligliptin can decrease the numbers of death. CONCLUSION: As the new kind of hypoglycemic agent, dipeptidyl peptidase-Ⅳ (DPP-4) inhibitor teneligliptin can reduce the blood glucose effectively with no increased risk of hypoglycemia, protect the beta-cell function of type 2 diabetic mellitus and decrease the rate of diabetes complications and death.

Key words: dipeptidyl peptidase-Ⅳ inhibitor, teneligliptin, type 2 diabetes mellitus, systematic review, Markov model

中图分类号:

R587.1

张春燕，范小冬，秦元，孔文强，周春阳，杜彪. 特力利汀治疗2型糖尿病长期效果的Markov模型[J]. 中国临床药理学与治疗学, 2018, 23(1): 65-72.

ZHANG Chunyan, FAN Xiaodong, QIN Yuan, KONG Wenqiang, ZHOU Chunyang, DU Biao. Markov model to assess long-term effects of teneligliptin in treatment of type 2 diabetes mellitus[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(1): 65-72.

参考文献

［1］Sharma SK, Panneerselvam A, Singh KP, et al. Teneligliptin in management of type 2 diabetes mellitus［J］. Diabetes Metab Syndr Obes, 2016, 9: 251-260.
［2］Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors［J］. Diabetes Obes Metab, 2016, 18(3): 203-216.
［3］Yassin SA, Aroda VR. Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale［J］.Drug Des Devel Ther, 2017, 21(11): 923-937.
［4］Bryson A, Jennings PE, Deak L, et al. The efficacy and safety of teneligliptin added to ongoing metformin monotherapy in patients with type 2 diabetes: a randomized study with open label extension［J］. Expert Opin Pharmacother, 2016, 17(10): 1309-1316.
［5］Eto T, Inoue S, Kadowaki T. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial［J］. Diabetes Obes Metab, 2012, 14(11): 1040-1046.
［6］Higgins J, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.1.0［M］// Cochrane handbook for systematic reviews of interventions /. Wiley-Blackwell, 2011: 102-108.
［7］Kadowaki T, Kondo K. Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus［J］. J Diabes Investig, 2013, 4(6): 576-584.
［8］Kadowaki T, Kondo K. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus［J］. Diabetes Obes Metab, 2013, 15(9): 810-818.
［9］Kadowaki T, Kondo K. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension［J］. Diabetes Obes Metab, 2014, 16(5): 418-425.
［10］Kim MK, Rhee EJ, Han KA, et al. Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial［J］. Diabetes Obes Metab, 2015, 17(3): 309-312.
［11］Hong S, Park CY, Han KA, et al. Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo‐controlled phase III trial［J］. Diabetes Obes Metab, 2016, 18(5): 528-532.
［12］高雯雯. DPP-4抑制剂联合二甲双胍治疗T2DM的短期效果及长期药物经济学评价［D］. 山东大学, 2016.
［13］United Kingdom Prospective Diabetes Study Group. Blood glucose control with metformin on complications in overweight patients with type 2 diabetes［J］. Lancet, 1998, 352: 854-865.
［14］Clark CM Jr. The burden of chronic hyperglycemia［J］. Diabtes Care, 1998, 21(suppl3): 32-34.
［15］Petitti D. Meta-analysis, decision analysis, and cost-effectiveness analysis［J］. 2nd ed. New York: Oxford University Press, 2000, 141-168.
［16］杨硕, 姜晓笛. 利格列汀联合门冬胰岛素50治疗肝源性糖尿病的效果观察［J］. 临床肝胆病杂志, 2017, 33(5): 928-931.
［17］付兴. 肠促胰素的应用与急、慢性胰腺炎发生风险的相关性研究［J］. 临床肝胆病杂志, 2017, 33(1): 35.
［18］Rizza RA. Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy［J］. Diabetes, 2010, 59(11): 697-707.
［19］Jung KY, Kim KM, Lim S. Therapeutic approaches for preserving or restoring pancreatic β-cell function and mass［J］. Diabetes Metab J, 2014, 38(6): 426-436.
［20］D'Alessio DA, Denney AM, Hermiller LM, et al. Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes［J］. J Clin Endocrinol Metab, 2009, 94(1): 81-88.
［21］DeFronzo RA, Fleck PR, Wilson CA, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study［J］. Diabetes Care, 2008, 31(12): 2315-2317.
［22］Del PS, Barnett AH, Huisman H, et al. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial［J］. Diabetes Obes Metab, 2011, 13(3): 258-267.
［23］Morita A, Mukai E, Hiratsuka A, et al. Distinct effects of dipeptidyl peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist on islet morphology and function［J］. Endocrine, 2016, 51(3): 1-11.

[1]	马言, 田高鹏, 石兴文, 孙婷, 谢晶晶, 甄东户. 探讨T2DM人群中25（OH）D与代谢相关性脂肪肝的相关性[J]. 中国临床药理学与治疗学, 2023, 28(9): 1018-1026.
[2]	马仙康, 杨丽霞, 崔阳阳, 米登海. 当归多糖通过抑制GRP78、p-PERK、p-Eif2α表达改善糖尿病KK-Ay小鼠肝内质网应激[J]. 中国临床药理学与治疗学, 2023, 28(8): 926-936.
[3]	侯瑞英, 郭莉阁, 焦伟杰, 杜蕾, 吴桂月, 赵旭. 消渴舒方对2型糖尿病模型大鼠血清炎症因子的影响及其机制研究[J]. 中国临床药理学与治疗学, 2023, 28(4): 377-382.
[4]	赵世峰, 宋向明, 姚建平. 新型胰高血糖素样肽-1受体/葡萄糖依赖性促胰岛素多肽受体双重激动剂——Tirzepatide[J]. 中国临床药理学与治疗学, 2023, 28(2): 220-227.
[5]	杜小雨, 李宇蒙, 吴惠珍, 邱博. 多格列艾汀治疗2型糖尿病的药理作用和临床评价[J]. 中国临床药理学与治疗学, 2023, 28(10): 1177-1183.
[6]	蔡静, 潘斌晶, 刘靖芳. 降糖药物与肌肉减少症关系的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(1): 101-108.
[7]	翟葳葳, 余巧玲, 刘平, 邱博, 吴惠珍. 非奈利酮在2型糖尿病合并慢性肾病治疗中的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(9): 1067-1074.
[8]	卢森林, 刘欣元, 王吉莉, 黄晓飞. 病毒载体介导的基因治疗在2型糖尿病中的研究进展[J]. 中国临床药理学与治疗学, 2022, 27(7): 800-807.
[9]	曾晓凡, 许宜琪, 刘书, 吴茜, 李自保, 何俊俊, 金岳龙, 赵永莉, 何春玲, 高家林. 回顾性分析小剂量阿司匹林对2型糖尿病病人非致死性心梗和脑梗一级预防的作用[J]. 中国临床药理学与治疗学, 2022, 27(6): 665-671.
[10]	邵茜, 郁亚南, 黄钰涵, 王晓彤, 凌宏威, 吕冬梅, 王涛. 艾塞那肽降低2型糖尿病患者体重的预测因素研究[J]. 中国临床药理学与治疗学, 2022, 27(3): 287-294.
[11]	代红雨, 杨坤, 胡如春, 周红梅, 马佩敏, 郝倩. 0.25%罗哌卡因用于糖尿病患者坐骨神经阻滞的时效研究[J]. 中国临床药理学与治疗学, 2022, 27(11): 1278-1284.
[12]	陈倩, 王亚峰, 朵德龙, 常亚娥, 严英俊, 段坤坤. 琥珀酸曲格列汀对2型糖尿病小鼠肠道菌群的改变[J]. 中国临床药理学与治疗学, 2022, 27(1): 15-24.
[13]	王春玲, 周仁精, 冯瑞, 吴燕能. 脂联素45 T/G基因多态性对利拉鲁肽治疗2型糖尿病患者的临床疗效[J]. 中国临床药理学与治疗学, 2021, 26(3): 312-317.
[14]	徐永霞, 谢明珠, 宫牧雪, 黄嘉莹, 赵丽, 朱德发. 25羟维生素D对老年2型糖尿病患者胰岛β细胞功能的影响[J]. 中国临床药理学与治疗学, 2020, 25(9): 1021-1026.
[15]	赵海玲, 张浩军, 赵婷婷, 严美花, 董晞, 马亮, 李平. PNPLA2基因多态性与中国汉族2型糖尿病患者缺血性脑卒中的相关性研究[J]. 中国临床药理学与治疗学, 2020, 25(6): 664-669.

特力利汀治疗2型糖尿病长期效果的Markov模型

Markov model to assess long-term effects of teneligliptin in treatment of type 2 diabetes mellitus

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价